Evidence map›Paper›PMID 35906901›Full record

ArticleJournal of veterinary internal medicine2022

Pharmacokinetic and pharmacodynamic properties of orally administered torasemide in healthy cats.

Marine Roche-Catholy, Dominique Paepe, Mathias Devreese, Bart J G Broeckx, Frederique Woehrlé, Marc Schneider, Andrea Garcia de Salazar Alcala, Arnaut Hellemans, Pascale Smets

Open access · goldAbstract read
In one paragraph

Article in Journal of veterinary internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Feline comorbidities: cardiovascular and kidney diseases.Journal of feline medicine and surgery · 2026
    Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 4 countries.

Marine Roche-CatholySmall Animal Department, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.ORCID https://orcid.org/0000-0002-5117-0638
Dominique PaepeSmall Animal Department, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.ORCID https://orcid.org/0000-0003-2919-1712
Mathias DevreeseDepartment of Pathobiology, Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Bart J G BroeckxLaboratory of Animal Genetics, Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium.ORCID https://orcid.org/0000-0001-6742-3911
Frederique WoehrléGlobal Drug Development Division, Lure, France.ORCID https://orcid.org/0000-0003-2188-854X
Marc SchneiderGlobal Drug Development Division, Lure, France.
Andrea Garcia de Salazar AlcalaAvogadro LS, Fontenilles, France.
Arnaut HellemansSmall Animal Department, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.ORCID https://orcid.org/0000-0002-5373-3131
Pascale SmetsSmall Animal Department, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Ghent University · BECenter for Global Development · USKellogg's (Canada) · CA

Funding

Vetoquinol
6 · The paper itself

Abstract

backgroundIn people and dogs, torasemide has higher bioavailability, longer half-life, and longer duration of action than equivalent doses of furosemide but data regarding pharmacological properties of torasemide in cats are limited.

objectiveTo assess pharmacokinetic and pharmacodynamic parameters of torasemide in healthy cats, and to investigate the effects of a single administration of torasemide on indicators of diuresis, plasma creatinine concentration, blood pressure, electrolyte concentrations and markers of the renin-angiotensin-aldosterone system (RAAS). ANIMALS: Six clinically healthy adult European shorthair cats.

methodsRandomized 4-period crossover design with 3 groups and 4 treatments. Pharmacokinetic parameters were obtained using a noncompartmental analysis, and the clinically effective dose was assessed using a Hill model.

resultsMean absolute bioavailability was estimated at 88.1%. Mean total body clearance was 3.64 mL/h/kg and mean terminal half-life was 12.9 hours. Urine output significantly increased after torasemide administration (P < .001). The urine sodium : potassium ratio (uNa : uK) paralleled and was statistically correlated to urine output (P < .001). Administration of a single torasemide dose led to a significant dose-dependent increase in urine aldosterone : creatinine ratio (uAldo : C; P < .001) and a transient decrease in plasma potassium concentration (P < .001) but did not affect blood pressure or plasma creatinine concentration. CONCLUSIONS AND CLINICAL IMPORTANCE: A single torasemide dose leads to a significant increase in diuresis and renin-angiotensin-aldosterone system (RAAS) activation in healthy cats, with high absolute bioavailability, and without clinically relevant adverse effects. Pharmacokinetic parameters indicate that once daily dosing of 0.27 mg/kg may be appropriate in a clinical setting.

Indexed as

DiureticsFurosemideAldosteroneAnimalsCatsCreatinineDogsElectrolytesHumansPotassiumSodiumSulfonamidesTorsemideAldosteroneCreatinineDiureticsElectrolytesFurosemidePotassiumSodiumSulfonamidesTorsemidecongestive heart failurediureticfelinehypertrophic cardiomyopathy

Identifiers

PMID35906901
PMCPMC9511087
OpenAlexW4288758373

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.